Abstract:Background and Objectives: Myopia is the most widespread ocular disorder globally and its prevalence has been increasing over the past decades. Atropine eye drops stand out as the only pharmacological intervention used in clinical practice to control myopia progression. The aim of this study was to explore the effect of 0.01% atropine eye drops on myopia progression. Patients and Methods: Healthy children aged 6-12 years with cycloplegic spherical equivalent (SE) from -0.5 D to -5.0 D and astigmatism ≤1.5 D were included. Myopia progression was assessed by changes in SE and axial length (AL) over 1 year and SE changes 1 year before the study enrollment and during the 1-year follow-up. Adverse events were evaluated based on complaints reported by either parents or the children themselves during follow-up visits. Results: The analysis involved 55 patients in the 0.01% atropine eye drops group and 66 in the control group. After the 1-year follow-up, the change in SE was -0.50 (-2.25-0.50) D in the control group compared to -0.50 (-1.50-0.50) D in the 0.01% atropine group (p = 0.935); AL change was 0.31 (0.18) mm in the control group and 0.29 (0.18) mm in the 0.01% atropine group (p = 0.480). The change in SE was -0.68 (-2.0--0.25) D/year before the study and remained similar -0.50 (-2.25-0.25) D over the 1-year follow-up in the control group (p = 0.111); SE change was reduced from -1.01 (-2.0--0.25) D/year before the study to -0.50 (-1.5-0.5) D over the 1-year follow-up in the 0.01% atropine group (p < 0.001). In the 0.01% atropine group, ten (16.4%) children experienced mild adverse events, including blurred near vision, ocular discomfort, photophobia, dry eyes, and anisocoria. Conclusions: Compared to the control group, the administration of 0.01% atropine eye drops demonstrated no significant effect on changes in SE and AL over a 1-year follow-up. However, children in the 0.01% atropine group initially experienced higher myopia progression, which decreased with treatment over the course of 1 year. Future studies should explore the long-term effects, rebound effects, potential genetic associations, and efficacy of higher doses of atropine in managing myopia progression.

Discrete event system techniques for CIM: Guest editorial

KNOWLEDGE AND CHARACTER IN COMMUNITY HOSPITAL MEDICINE.

Myopia control strategies: A systematic review and meta‐meta‐analysis

Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis

Strength and lactone formation of gluconic acid.

High myopia: Reviews of myopia control strategies and myopia complications

[Clinical and radiologic aspects of hyperparathyroidism. On scintigraphy in the diagnosis of parathyroid adenoma].

Regulation of renal functional development.

Advances in myopia control strategies for children

Efficacy of atropine for myopia control in children: A meta-analysis of randomized controlled trials

Myopia control: Seeing beyond efficacy

Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study

Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients

Effective Decrease in Myopia Progression With Two Mechanisms of Management

Both NOR and NAND Embedded Hybrid Flash for S-SIM Application Using 90 nm Process Technology

Nutrition of Australian Aboriginal infants and children

Author Correction: Synergistic Effects of Defocus-Incorporated Multiple Segments and Atropine in Slowing the Progression of Myopia

Work group IV: increasing the capacity of parents, families, and adults living with adolescents to improve adolescent health outcomes.

Effects of atropine eyedrops at ten different concentrations for myopia control in children: A systematic review on meta-analysis

Efficacy and Safety of Low Dose Atropine 0.01% in Slowing of Progression of Myopia

Five-year results of atropine 0.01% efficacy in the myopia control in a European population